Market
What will be the total revenue generated for PTC from PTC518 by end of 2025?
3
Resolution / Starting Odds
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
More than $2 billion • 25%
PTC Therapeutics financial statements and press releases
Story
PTC Therapeutics and Novartis Partner on $2.9 Billion Huntington's Disease Drug Deal with $1 Billion Upfront
Dec 2, 2024, 12:04 PM
PTC Therapeutics has entered into a global license and collaboration agreement with Novartis for the development of PTC518, an experimental drug targeting Huntington's disease. Under the terms of the deal, PTC Therapeutics will receive $1 billion in cash upfront. Additionally, the companies will share U.S. profits and losses on a 40/60 basis, with PTC receiving 40% and Novartis 60%. The total value of the agreement could reach up to $2.9 billion, contingent on milestone achievements. This collaboration represents a significant step in advancing the development of PTC518, which addresses a rare neurological disorder.
View original story
Similar markets
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trial extended • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
More than $2 billion • 25%
Less than $500 million • 25%
Less than 5% increase • 25%
More than 15% increase • 25%
10% to 15% increase • 25%
5% to 10% increase • 25%
Europe • 25%
Other regions • 25%
Asia-Pacific • 25%
North America • 25%
